FIELD: biochemistry.
SUBSTANCE: invention relates to peptide-nucleic acid derivatives targeting a portion of human SCN9A pre-mRNA. Peptide-nucleic acid derivatives effectively induce the formation of SCN9A mRNA splicing variants in cells and are suitable for safe treatment of pain or conditions involving Nav1.7 activity.
EFFECT: safe treatment of pain or conditions involving Nav1.7 activity.
14 cl, 17 dwg, 2 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTISENSE ANALGESIC FOR SCN9A | 2018 |
|
RU2762293C2 |
| EXON SKIP WITH PEPTIDONUCLEIC ACID DERIVATIVES | 2017 |
|
RU2786637C2 |
| ANTISENSE OLIGONUCLEOTIDES TO HIF-1-ALPHA | 2017 |
|
RU2753517C2 |
| ANTISENSE OLIGONUCLEOTIDES OF ANDROGEN RECEPTOR | 2017 |
|
RU2753966C2 |
| ANTISENSE OLIGONUCLEOTIDES FOR SNAP25 | 2017 |
|
RU2766701C2 |
| ANTISENSE TYROSINASE OLIGONUCLEOTIDES | 2018 |
|
RU2778786C2 |
| ANTISENSE OLIGONUCLEOTIDES OF ACETYL-COA-CARBOXYLASE-2 | 2019 |
|
RU2807629C2 |
| ANTISENSE OLIGONUCLEOTIDES OF MATRIX METALLOPROTEINASE-1 | 2019 |
|
RU2802418C2 |
| PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | 2009 |
|
RU2564032C2 |
| COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION | 2016 |
|
RU2736574C2 |
